Last update April 1, 2023

Abacavir (ABC)

Compatible

Safe substance and/or breastfeeding is the best option.

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV. Indicated for children older than 3 mo. Oral administration in one or two daily doses.

It is excreted in breast milk in clinically insignificant amounts (Aebi 2022, Shapiro 2013) and no problems have been observed in infants whose mothers have taken it. (Kobbe 2016)

Plasma levels in these infants were very low. (Aebi 2022, Shapiro 2013)

No cases of hyperprolactinemia and/or galactorrhea attributed to Abacavir have been described in women, although there have been cases in men. (Hutchinson 2000).


See below the information of this related product:

Alternatives

We do not have alternatives for Abacavir (ABC) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Abacavir (ABC) is also known as


Abacavir (ABC) in other languages or writings:

Group

Abacavir (ABC) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Abacavir (ABC) in its composition:

List of 15 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 83 %
Molecular weight 296 daltons
Protein Binding 49 %
VD 0.86 ± 0.15 l/Kg
pKa 15.4 -
Tmax 2 hours
T½ 1.5 ± 0.6 hours
M/P ratio 1.0 (0.8 - 1.7) -
Theoretical Dose 0.01 (0.01–0.02) mg/Kg/d
Relative Dose 0.34 (0.17 - 0.46) %
Ped.Relat.Dose 0.09 %

References

  1. Aebi-Popp K, Kahlert CR, Crisinel PA, Decosterd L, Saldanha SA, Hoesli I, Martinez De Tejada B, Duppenthaler A, Rauch A, Marzolini C; Swiss Mother and Child HIV Cohort Study (SHCS).. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother. 2022 Nov 28;77(12):3436-3442. Consulted on Dec. 16, 2022 Abstract Full text (link to original source)
  2. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS. 2016 Nov 13;30(17):2731-2733. No abstract available. Abstract Full text (link to original source)
  4. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18(4):585-90. Abstract Full text (link to original source)
  5. Ribera E, Tuset M, Martín M, del Cacho E. Características de los fármacos antirretrovirales. [Characteristics of antiretroviral drugs]. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. Abstract
  6. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010 Abstract Full text (link to original source)
  7. Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet. 2000 Sep 16;356(9234):1003-4. Abstract

Total visits

8,395

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM